Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359982 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
A Phase 1 study, sponsored by EpicentRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01359982 is a Phase 1 study that has completed, run by EpicentRx. The registered enrollment target is 26 participants.
The verdict
NCT01359982, a Phase 1 study, has completed, sponsored by EpicentRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.
Interventions
- DRUG RRx-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359982
The ClinicalTrials.gov registry entry for NCT01359982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RRx-001 is the first listed.
NCT01359982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359982 about?
NCT01359982 is a clinical study titled "Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects". The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor respons...
What is the current status of trial NCT01359982?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01359982?
The interventions under investigation include: RRx-001 (DRUG).
Who is sponsoring clinical trial NCT01359982?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.